Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05083182 · ClinicalTrials.gov registry record · Phase 3
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
A Phase 3 study of Arthritis, Juvenile, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
- 20
- Study locations
NCT05083182 is a Phase 3 study of Arthritis, Juvenile that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 50 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT05083182, a Phase 3 study of Arthritis, Juvenile, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juvenile psoriatic arthritis (jPsA).
Conditions Studied
Interventions
- DRUG Ustekinumab
- DRUG Guselkumab
Study Locations (20)
Other
- STAT Research S A - Ciudad Autonoma Buenos Aires
- Hospital de Ninos de Cordoba - Córdoba
- Instituto Medico Platense - La Plata
- Instituto Caici - Rosario
- Centro Medico Privado de Reumatologia - San Miguel de Tucumán
- Aarhus Universitetshospital - Aarhus
- Odense Universitets Hospital - Odense
- CHU de Caen - Caen
- Hopital de Bicetre - Le Kremlin-Bicêtre
- Hopital Nord Marseille - Marseille
- CHU de Toulouse Hopital des Enfants - Toulouse
California
- Childrens Hospital Los Angeles - Los Angeles
- UCLA - Los Angeles
New York
- Northwell Health - New York
- Montefiore Medical Center - The Bronx
Massachusetts
- Harvard Medical School - Boston Children's Hospital - Boston
North Carolina
- University of North Carolina - Chapel Hill
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Oregon
- Legacy Emanuel Medical Center - Portland
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-08-30 |
| Est. Completion | 2026-12-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05083182
The ClinicalTrials.gov registry entry for NCT05083182 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Arthritis, Juvenile appearing as the primary indexed condition, and to 2 interventions - of which Ustekinumab is the first listed.
NCT05083182 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT05083182 about?
NCT05083182 is a clinical study titled "A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis". The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juvenile psoriatic arthritis (jPsA).
What is the current status of trial NCT05083182?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2022-08-30. Estimated completion is 2026-12-05.
What conditions does trial NCT05083182 study?
This clinical trial studies the following conditions: Arthritis, Juvenile.
What interventions are being tested in trial NCT05083182?
The interventions under investigation include: Ustekinumab (DRUG), Guselkumab (DRUG).
Who is sponsoring clinical trial NCT05083182?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05083182 being conducted?
This trial has 20 study locations across California, Massachusetts, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Juvenile
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
RECRUITING · Phase 3
-
A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.